ZD6474 and
Docetaxel in Treating Patients With Locally Advanced or
Metastatic Non-Small Cell Lung Cancer (7/22/04)
-
Summary: Randomized phase II trial to compare
the effectiveness of different regimens of ZD6474 combined with
docetaxel in treating patients who have locally advanced or
metastaticnon-small cell lung cancer that is refractory to
platinum-based chemotherapy.
-
Trial offered in: California
(Click the above link for contact information)
Phase III, Study of TLK286
vs. Gefinitib in Locally Advanced or Metastatic Non-Small
Cell Lung Cancer (6/26/04)
-
Summary: The purpose of this study is to
determine if TLK286 is more effective than gefitinib (Iressa)
in the treatment of non-small cell lung cancer
-
Trial offered in: Arizona, California,
District of Columbia, Florida, Georgia, Illinois, Indiana,
Maryland, Massachusetts, Michigan, Missouri, Nebraska, New
Mexico, New York, North Carolina, North Dakota, South Carolina,
Tennessee, Texas, Washington
(Click the above link for contact information)
Oral ZD1839
(IRESSA(R)) Versus
Intravenous Docetaxel
(TAXOTERE(R))
in Patients With Non-Small Cell Lung Cancer
(6/7/04)
-
Summary: The purpose of this study is to
compare the overall survival between ZD1839 (Iressa?) and
docetaxel. Patients must be 18 years or over with locally
advanced or metastatic recurrent non-small cell lung cancer
that have previously received platinum-based chemotherapy.
Platinum-based chemotherapy regimens will most commonly consist
of either cisplatin or carboplatin in combination with one of
the following chemotherapeutic agents: paclitaxel, gemcitabine,
vinorelbine, or docetaxel. Patients will either be given ZD1839
250mg/day orally or docetaxel 75 mg intravenously over 1 hour
every 3 weeks.
-
Trial offered in: Alabama, California,
Florida, Illinois, New York, North Carolina, Ohio,
Pennsylvania, Tennessee, Texas, Virginia
(Click the above link for contact information)
BAY 43-9006 in
Treating Patients With Refractory Non-Small Cell Lung
Cancer (May, 2004)
-
Summary: Randomized phase II trial to study
the effectiveness of BAY 43-9006 in treating patients who have
refractory non-small cell lung cancer
-
Trial offered in: Alabama, Arizona,
California, Colorado, Delaware, District of Columbia, Florida,
Georgia, Illinois, Indiana, Iowa, Kansas, Louisiana, Maryland,
Massachusetts, Michigan, Minnesota, Nebraska, Nevada, New
Hampshire, New Jersey , New Mexico, New York, North Dakota,
Ohio, Oklahoma, Pennsylvania, South Dakota,
Tennessee, Texas, Wisconsin
(Click the above link for contact information)
Gemcitabine,
Carboplatin, and Bortezomib in Treating Patients With
Advanced or Recurrent Non-Small Cell Lung Cancer (May,
2004)
-
Summary: Phase II trial to study the
effectiveness of combining bortezomib with gemcitabine and
carboplatin in treating patients who have advanced or
recurrentnon-small cell lung cancer that has not been
previously treated with chemotherapy.
-
Trial offered in: Alabama, Arizona, Arkansas,
California, Colorado, District of Columbia, Florida, Georgia,
Hawaii, Illinois, Kansas, Kentucky, Louisiana, Massachusetts,
Michigan, Mississippi, Missouri, Montana, New Jersey, New
Mexico, New York, North Carolina, Ohio, Oregon, South Carolina,
Tennessee, Texas, Utah, Washington
(Click the above link for contact information)
Phase III, Alimta
(pemetrexed) in Patients with Non-Small Cell Lung Cancer
Who Have Failed a Prior Platinum-Containing Chemotherapy
(March 5, 2004)
-
Summary: The purposes of this study are to
determine: the safety of ALIMTA and any side effects that might
be associated with it; how much ALIMTA should be given to
patients.
It is possible that information collected during this study
will be analyzed by the Sponsor in the future to evaluate
ALIMTA for other possible uses or for other medical or
scientific purposes other than those currently proposed.
Although ALIMTA has been shown to be effective in some patients
with non-small-cell lung cancer, ALIMTA might not have
beneficial effects for all patients.
-
Trial offered in: Arkansas, California
(Click the above link for contact information)
Phase III,
Gemcitabine and Carboplatin Followed By Docetaxel in
Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung
Cancer
- Drugs used in chemotherapy, such as gemcitabine, carboplatin,
and docetaxel, use different ways to stop tumor cells from
dividing so they stop growing or die. Combining more than one
drug may kill more tumor cells. It is not yet known which
treatment regimen is more effective for stage IIIB or stage IV
non-small cell lung cancer. Randomized phase III trial to compare
the effectiveness of gemcitabine and carboplatin followed
immediately by docetaxel with that of giving delayed docetaxel in
treating patients who have stage IIIB or stage IV non-small cell
lung cancer.
-
Trial offered in: Ohio
(Click the above link for contact information)
* * * * * * * * * * *
Neither the Law Offices of Roger G. Worthington nor its
clients herein (including clients of other law firms) intend to
waive the attorney-client privilege by posting information about
these clients herein. The information contained herein is intended
to educate and inform asbestos cancer patients and their families
of potential medical and legal options. Roger Worthington is not a
medical doctor. Patients are advised to consult with a medical
doctor and/or an attorney if they have questions regarding this
information. The opinions expressed herein by persons other than
Roger Worthington are not necessarily endorsed by the Law Offices
of Roger G. Worthington, P.C. This is an open forum.
* * * * * * * * * * *
|